Akebia Therapeutics (NASDAQ:AKBA) announced its earnings results on Monday, March 12th. The biopharmaceutical company reported $0.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.61, Bloomberg Earnings reports. Akebia Therapeutics had a negative net margin of 43.21% and a negative return on equity of 100.28%. The firm had revenue of $87.32 million for the quarter, compared to analyst estimates of $66.00 million.
Shares of Akebia Therapeutics stock traded down $0.40 during trading hours on Thursday, reaching $9.48. The company’s stock had a trading volume of 650,284 shares, compared to its average volume of 434,047. Akebia Therapeutics has a one year low of $8.83 and a one year high of $20.25. The firm has a market capitalization of $526.34, a price-to-earnings ratio of -5.36 and a beta of 1.09.
AKBA has been the topic of a number of analyst reports. Mizuho reissued a “buy” rating and issued a $24.00 price objective on shares of Akebia Therapeutics in a research note on Tuesday, February 13th. BTIG Research initiated coverage on shares of Akebia Therapeutics in a research note on Thursday, December 7th. They issued a “buy” rating and a $30.00 price objective for the company. ValuEngine raised shares of Akebia Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. Zacks Investment Research downgraded shares of Akebia Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. Finally, Piper Jaffray initiated coverage on shares of Akebia Therapeutics in a research note on Monday, December 18th. They set an “overweight” rating and a $26.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $22.20.
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients.
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.